GeoVax, Inc - AIDS Vaccine Research, Vaccine Awareness GOVX
- 15 years ago
GeoVax Labs, Inc. (GOVX.OB), a clinical stage biotechnology company, develops human vaccines for diseases caused by human immunodeficiency virus (HIV) and other infectious agents. Its DNA (deoxyribonucleic acid) and MVA (Modified Vaccinia Ankara) vaccines are in Phase II human clinical trial by the HIV Vaccine Trials Network. The company was founded in 2001 and is based in Atlanta, Georgia.
GeoVax's AIDS (HIV-1) Vaccines, initially developed at Emory University by Dr. Harriet Robinson, currently GeoVax's Senior Vice President of Research and Development, in collaboration with researchers at the NIAID (NIH) and the U.S. Centers for Disease Control (CDC), are recombinant DNA and MVA vaccines. Our focus is on developing AIDS vaccines comprising the major HIV-1 subtypes (A, B and C). These vaccines can be used alone or in combination depending on a local infection. Our first priority is subtype B which is most common in North America, the European Union, Japan and Australia.
When administered in series, our AIDS vaccines induce strong cellular and humoral immunity (protection) in non human primates against multiple HIV-1 (AIDS virus) proteins. This suggests that GeoVax's vaccines will provide protection against the development of AIDS in HIV-1 virus infected people.
Our Progress * Excellent Preclinical Data * Phase 1 Preventative Human Trial of a Prototype DNA Completed Satisfactory * Four Phase 1A/IB Preventative Human Trials Combining DNA with MVA and Testing Different Regimens Started 2006. * Phase 2 Preventative Human Trial Started January 2009 * Planning for Therapeutic Trial to Test Vaccines' Treatment Potential Started 2008
GeoVax's AIDS (HIV-1) Vaccines, initially developed at Emory University by Dr. Harriet Robinson, currently GeoVax's Senior Vice President of Research and Development, in collaboration with researchers at the NIAID (NIH) and the U.S. Centers for Disease Control (CDC), are recombinant DNA and MVA vaccines. Our focus is on developing AIDS vaccines comprising the major HIV-1 subtypes (A, B and C). These vaccines can be used alone or in combination depending on a local infection. Our first priority is subtype B which is most common in North America, the European Union, Japan and Australia.
When administered in series, our AIDS vaccines induce strong cellular and humoral immunity (protection) in non human primates against multiple HIV-1 (AIDS virus) proteins. This suggests that GeoVax's vaccines will provide protection against the development of AIDS in HIV-1 virus infected people.
Our Progress * Excellent Preclinical Data * Phase 1 Preventative Human Trial of a Prototype DNA Completed Satisfactory * Four Phase 1A/IB Preventative Human Trials Combining DNA with MVA and Testing Different Regimens Started 2006. * Phase 2 Preventative Human Trial Started January 2009 * Planning for Therapeutic Trial to Test Vaccines' Treatment Potential Started 2008